Abstract: Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably ?-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

Abstract: A business method for converting and storing classification data of existing codes having different number of levels and different number of digits in each level in their hierarchal structure. The invention comprises converting the existing codes in an integrated manner to a tabular format, containing the description of existing codes, level of codes and links to the parent codes by a converting means and storing the said tabular format in the said data storage means, such that it is accessible by a common access means.

Abstract: An internet user using a browser (10) connects to a first server (30) and conducts transactions at the site (30). The user is transferred to a second server (32) along with data relating to the transactions via the user's browser program (10). A digital signature is added to the data prior to transfer. Before the user can access the second server (32), the digital signature is verified, thus promoting security and integrity of the transaction.

Abstract: An internet user using a browser (10) connects to a first server (30) and conducts transactions at the site (30). The user is transferred to a second server (32) along with data relating to the transactions via the user's browser program (10). A digital signature is added to the data prior to transfer. Before the user can access the second server (32), the digital signature is verified, thus promoting security and integrity of the transaction.

Abstract: Automatic pricing of remotely hosted applications permits users to enter customer data and flexibly prices various product offerings, product lines, and applications. An initial build of a computer system, modifications to an existing computer system configuration, extended services, and enhancements are incorporated. Errors are checked for and can be corrected.

Abstract: The present invention provides in a method for providing secure authentication using digital certificates, an improvement to enable the selective transfer of authentication data. The said method comprises presentation of basic authentication data certified by an accepted certifying authority, at the commencement of a secure transaction and transfer of additional individual authentication data units against specific requests, as and when required, thereby eliminating the risks associated with providing any authentication data that is not required for a particular transaction.

Abstract: Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably &bgr;-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

Abstract: Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably &bgr;-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.